CAPTRUST Financial Advisors’s BridgeBio Pharma BBIO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Sell	4,686 -432	-8%	-$30.3K	﹤0.01%	2459
2026 Q1	$380K	Buy	5,118 +1,404	+38%	+$102K	﹤0.01%	2225
2025 Q4	$284K	Buy	+3,714	New	+$244K	﹤0.01%	2289
2024 Q1	–	Sell	-25,997	Closed	-$1.05M	–	2192
2023 Q4	$1.05M	Sell	25,997 -4,273	-14%	-$128K	﹤0.01%	1234
2023 Q3	$798K	Buy	30,270 +10,845	+56%	+$308K	﹤0.01%	1334
2023 Q2	$334K	Buy	+19,425	New	+$292K	﹤0.01%	1890
2022 Q3	–	Sell	-1,034	Closed	-$9K	–	2252
2022 Q2	$9K	Sell	1,034 -100	-9%	-$836	﹤0.01%	3788
2022 Q1	$12K	Buy	1,134 +573	+102%	+$5.88K	﹤0.01%	3694
2021 Q4	$9K	Buy	561 +114	+26%	+$4.82K	﹤0.01%	3763
2021 Q3	$21K	Buy	447 +268	+150%	+$14.4K	﹤0.01%	3120
2021 Q2	$11K	Sell	179 -25	-12%	-$1.43K	﹤0.01%	3483
2021 Q1	$13K	Buy	+204	New	+$13.3K	﹤0.01%	3273

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

CAPTRUST Financial Advisors's BBIO Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its BridgeBio Pharma (BBIO) stake by 8.4% in Q2 2026, selling an estimated $30.3K and leaving 4,686 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

CAPTRUST Financial Advisors first reported a position in BBIO in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.05M in Q4 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

CAPTRUST Financial Advisors held 4,686 shares of BridgeBio Pharma worth $349K as of Q2 2026.
CAPTRUST Financial Advisors sold 432 BridgeBio Pharma shares in Q2 2026, an estimated $30.3K.
BridgeBio Pharma made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2459 holding.
CAPTRUST Financial Advisors first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 12 quarters since.
CAPTRUST Financial Advisors's BridgeBio Pharma position peaked at $1.05M in Q4 2023.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.